GSK has completed its acquisition of Canadian biotech 35Pharma in a deal valued at 950 million dollars, marking a further step in its strategy to expand its specialty medicines pipeline. The clinical stage company focuses on protein based therapeutics, adding new scientific capabilities to GSK’s research portfolio.

Central to the acquisition is HS235, an investigational therapy targeting pulmonary hypertension, a serious condition characterised by high blood pressure in the lungs and limited treatment options. The candidate has completed early stage studies and is expected to move into further clinical trials shortly.

HS235 is designed to offer potential advantages over existing treatments, including a differentiated safety profile and possible metabolic benefits. Its addition supports GSK’s focus on respiratory, immunology and inflammation, while addressing diseases linked to vascular and metabolic dysfunction.

The deal, first announced in February, reflects GSK’s continued investment in targeted acquisitions to strengthen its pipeline and deliver future growth, particularly in areas of high unmet medical need such as pulmonary hypertension.